David Leppert
Research Subjects
David Leppert has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A. Probst
From the Departments of Research (Dr. LeppertB. Erne, and C. Grygar), Neurology (Drs. Leppert, Huber, Steck, and Fuhr), and Pathology (Dr. Probst), University Hospitals, Basel, Switzerland; Hôpital de Bicêtre (Dr. Said), Paris, France; British Biotech Pharmaceuticals, Ltd. (Dr. Miller); and Laboratory of Physiology (Dr. Hughes), University of Oxford, UK
1 shared publicationA.J. Steck
From the Departments of Research (Dr. LeppertB. Erne, and C. Grygar), Neurology (Drs. Leppert, Huber, Steck, and Fuhr), and Pathology (Dr. Probst), University Hospitals, Basel, Switzerland; Hôpital de Bicêtre (Dr. Said), Paris, France; British Biotech Pharmaceuticals, Ltd. (Dr. Miller); and Laboratory of Physiology (Dr. Hughes), University of Oxford, UK
1 shared publicationB. Erne
From the Departments of Research (Dr. LeppertB. Erne, and C. Grygar), Neurology (Drs. Leppert, Huber, Steck, and Fuhr), and Pathology (Dr. Probst), University Hospitals, Basel, Switzerland; Hôpital de Bicêtre (Dr. Said), Paris, France; British Biotech Pharmaceuticals, Ltd. (Dr. Miller); and Laboratory of Physiology (Dr. Hughes), University of Oxford, UK
1 shared publication- Beat Schaer
Department of Cardiology, University Hospital, Basel, Switzerland
1 shared publication C. Grygar
From the Departments of Research (Dr. LeppertB. Erne, and C. Grygar), Neurology (Drs. Leppert, Huber, Steck, and Fuhr), and Pathology (Dr. Probst), University Hospitals, Basel, Switzerland; Hôpital de Bicêtre (Dr. Said), Paris, France; British Biotech Pharmaceuticals, Ltd. (Dr. Miller); and Laboratory of Physiology (Dr. Hughes), University of Oxford, UK
1 shared publicationG. Said
From the Departments of Research (Dr. LeppertB. Erne, and C. Grygar), Neurology (Drs. Leppert, Huber, Steck, and Fuhr), and Pathology (Dr. Probst), University Hospitals, Basel, Switzerland; Hôpital de Bicêtre (Dr. Said), Paris, France; British Biotech Pharmaceuticals, Ltd. (Dr. Miller); and Laboratory of Physiology (Dr. Hughes), University of Oxford, UK
1 shared publication
Latest Publications
- 14 September 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (5) , E11
Syncope during EEG recording
- 14 September 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (5) , E11
Syncope during EEG recording
- 1 July 1999
- Published by Wolters Kluwer Health in Neurology
- Vol. 53 (1) , 62
Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy
Objective: To determine the expression pattern and cellular source of matrix metalloproteinases (MMPs) in chronic inflammatory demyelinating polyneuropathy (CIDP) and nonsystemic vasculitic neuropathy (NSVN). Background: MMPs are endopeptidases involved in tissue destruction and infiltration by immune cells in multiple sclerosis and Guillain-Barré syndrome. Enzyme inhibitors of MMPs attenuate clinical symptoms in corresponding animal models of these diseases. MMP inhibition may therefore be a novel approach for the treatment of CIDP and NSVN. However, the spectrum of MMPs expressed in chronic inflammatory neuropathies has not been established. Methods: The expression of MMP-2, MMP-3, MMP-7, and MMP-9 in T cells, macrophages, and stromal cells in CIDP, NSVN, and noninflammatory neuropathies (NIN) was quantitated by immunohistochemistry. Results were correlated with clinical and electrophysiologic findings. Results: The production of MMP-2 and MMP-9 is increased in nerve tissue in CIDP and NSVN compared with NIN. T cells are the predominant source of MMP-2 and MMP-9 in CIDP and NSVN, whereas macrophages contribute only to a minor extent. Stromal cells of the perineurium/epineurium are an additional source of MMP-2 in NSVN, but not in CIDP. Expression of MMP-3 and MMP-7 was not detectable in CIDP or NSVN. Expression of MMP-2 and MMP-9 did not correlate with clinical disease activity and electrophysiologic measurements. Conclusions: The upregulation of MMP-2 and MMP-9 is a specific feature of CIDP and NSVN, and selective inhibitors of these enzymes could be used to prevent inflammatory tissue damage. The similar increase of MMP-2 and MMP-9 in both demyelinating (CIDP) and nondemyelinating (NSVN) neuropathies raises doubts about whether MMPs play a primary role in demyelination.
- 1 July 1999
- Published by Wolters Kluwer Health in Neurology
- Vol. 53 (1) , 62
Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy
Objective: To determine the expression pattern and cellular source of matrix metalloproteinases (MMPs) in chronic inflammatory demyelinating polyneuropathy (CIDP) and nonsystemic vasculitic neuropathy (NSVN). Background: MMPs are endopeptidases involved in tissue destruction and infiltration by immune cells in multiple sclerosis and Guillain-Barré syndrome. Enzyme inhibitors of MMPs attenuate clinical symptoms in corresponding animal models of these diseases. MMP inhibition may therefore be a novel approach for the treatment of CIDP and NSVN. However, the spectrum of MMPs expressed in chronic inflammatory neuropathies has not been established. Methods: The expression of MMP-2, MMP-3, MMP-7, and MMP-9 in T cells, macrophages, and stromal cells in CIDP, NSVN, and noninflammatory neuropathies (NIN) was quantitated by immunohistochemistry. Results were correlated with clinical and electrophysiologic findings. Results: The production of MMP-2 and MMP-9 is increased in nerve tissue in CIDP and NSVN compared with NIN. T cells are the predominant source of MMP-2 and MMP-9 in CIDP and NSVN, whereas macrophages contribute only to a minor extent. Stromal cells of the perineurium/epineurium are an additional source of MMP-2 in NSVN, but not in CIDP. Expression of MMP-3 and MMP-7 was not detectable in CIDP or NSVN. Expression of MMP-2 and MMP-9 did not correlate with clinical disease activity and electrophysiologic measurements. Conclusions: The upregulation of MMP-2 and MMP-9 is a specific feature of CIDP and NSVN, and selective inhibitors of these enzymes could be used to prevent inflammatory tissue damage. The similar increase of MMP-2 and MMP-9 in both demyelinating (CIDP) and nondemyelinating (NSVN) neuropathies raises doubts about whether MMPs play a primary role in demyelination.